Podcast
MSL Talk: Tom Caravela, Giovanni Passiatore
3 Things I wish I knew about being a MSL
Summary
In this episode, Tom Caravela welcomes Mitchell D’Rozario from Genentech Roche to share his journey into the MSL role. Mitchell provides three key insights he wishes he had known before becoming an MSL and poses thought-provoking questions to Tom. The discussion covers staying motivated and purpose-driven, exploring alternative career paths in the pharmaceutical industry, and the challenges of building relationships in a virtual environment. They also delve into the changing landscape of conferences and the importance of face-to-face interactions. The episode concludes with closing remarks, gratitude, and a request for subscription and feedback.
My guest today is Mitchell D’Rozario, Medical Science Liaison at Genentech and we discuss the 3 things he wished he knew about being an MSL.
In this episode we discuss:
- Mitchell’s background and breaking into the industry
- 3 things he wishes he had known about being an MSL
- What Tom wishes aspiring MSLs knew about the role
- What Tom looks for when screening candidates for roles
- Some red flags Tom notices often
- What keeps Mitchell on track
- What Mitchell learned in 2020 going through pandemic and how it changed him as an MSL
- His opinion of what 2021 will look like for field medical and what MSLs might expect
MSL career insights, pharmaceutical industry careers, virtual relationship building, Medical Science Liaison challenges, conference networking importance
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Giovanni Passiatore
Article
Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
Article
Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
Article
Alyson Haslam, PhD; Vinay Prasad, MD, MPH
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Article
Ali Raza Khaki
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
Article
iNIZIO